Literature DB >> 6302327

Physical mapping of the mutation in an antigenic variant of herpes simplex virus type 1 by use of an immunoreactive plaque assay.

T C Holland, R M Sandri-Goldin, L E Holland, S D Marlin, M Levine, J C Glorioso.   

Abstract

Two mutations affecting herpes simplex virus type 1 glycoprotein B were mapped by marker rescue using cloned sequences of wild-type herpes simplex virus type 1 strain KOS DNA. One mutant, tsB5, is a temperature-sensitive mutant which does not express mature, functional glycoprotein B at the nonpermissive temperature. The other mutant, marB1.1, expresses an antigenic variant of glycoprotein B and was selected for resistance to neutralization by a monoclonal antibody. The mutation in tsB5 mapped to a 1.2-kilobase segment of the herpes simplex virus type 1 genome between coordinates 0.361 and 0.368, whereas the mutation in marB1.1 mapped to a 1.6-kilobase segment between coordinates 0.350 and 0.361. An in situ enzyme immunoassay was used to detect plaques of recombinant wild-type virus among the progeny of transfections with mutant marB1.1 DNA and wild-type DNA fragments.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6302327      PMCID: PMC255171     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  Cell fusion induced by herpes simplex virus is promoted and suppressed by different viral glycoproteins.

Authors:  R Manservigi; P G Spear; A Buchan
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

2.  Herpes simplex virus protein synthesis in the presence of 2-deoxy-D-glucose.

Authors:  R J Courtney
Journal:  Virology       Date:  1976-08       Impact factor: 3.616

3.  Immune interactions with cells infected with herpes simplex virus: antibodies to radioiodinated surface antigens.

Authors:  J C Glorioso; J W Smith
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

4.  Effect of tunicamycin on herpes simplex virus glycoproteins and infectious virus production.

Authors:  L I Pizer; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1980-04       Impact factor: 5.103

5.  A virion-associated glycoprotein essential for infectivity of herpes simplex virus type 1.

Authors:  S P Little; J T Jofre; R J Courtney; P A Schaffer
Journal:  Virology       Date:  1981-11       Impact factor: 3.616

6.  Nucleotide sequences of herpes simplex virus type 1 (HSV-1) affecting virus entry, cell fusion, and production of glycoprotein gb (VP7).

Authors:  N DeLuca; D J Bzik; V C Bond; S Person; W Snipes
Journal:  Virology       Date:  1982-10-30       Impact factor: 3.616

7.  Visualization of minute centers of viral infection in unfixed cell cultures by an enzyme-linked antibody assay.

Authors:  K O Smith; W L Kennell; D L Lamm
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

8.  Alterations in glycoprotein gB specified by mutants and their partial revertants in herpes simplex virus type 1 and relationship to other mutant phenotypes.

Authors:  M L Haffey; P G Spear
Journal:  J Virol       Date:  1980-07       Impact factor: 5.103

9.  Antigenic variants of herpes simplex virus selected with glycoprotein-specific monoclonal antibodies.

Authors:  T C Holland; S D Marlin; M Levine; J Glorioso
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

10.  Cloning of herpes simplex virus type 1 sequences representing the whole genome.

Authors:  A L Goldin; R M Sandri-Goldin; M Levine; J C Glorioso
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

View more
  60 in total

1.  The attenuated pseudorabies virus strain Bartha fails to package the tegument proteins Us3 and VP22.

Authors:  Mathew G Lyman; Gretchen L Demmin; Bruce W Banfield
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Site-specific insertion of DNA into a pseudorabies virus vector.

Authors:  B Sauer; M Whealy; A Robbins; L Enquist
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

3.  Identification of a site on herpes simplex virus type 1 glycoprotein D that is essential for infectivity.

Authors:  M I Muggeridge; W C Wilcox; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

4.  Partial resistance to gD-mediated interference conferred by mutations affecting herpes simplex virus type 1 gC and gK.

Authors:  P E Pertel; P G Spear
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Mutations in the C-terminal hydrophobic domain of pseudorabies virus gIII affect both membrane anchoring and protein export.

Authors:  K A Solomon; A K Robbins; L W Enquist
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

6.  Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity.

Authors:  B C Herold; D WuDunn; N Soltys; P G Spear
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

7.  Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity.

Authors:  G Kümel; H C Kaerner; M Levine; C H Schröder; J C Glorioso
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

8.  Antigenic variation (mar mutations) in herpes simplex virus glycoprotein B can induce temperature-dependent alterations in gB processing and virus production.

Authors:  S D Marlin; S L Highlander; T C Holland; M Levine; J C Glorioso
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

9.  HveA (herpesvirus entry mediator A), a coreceptor for herpes simplex virus entry, also participates in virus-induced cell fusion.

Authors:  T Terry-Allison; R I Montgomery; J C Whitbeck; R Xu; G H Cohen; R J Eisenberg; P G Spear
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry.

Authors:  B C Herold; S I Gerber; B J Belval; A M Siston; N Shulman
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.